Cargando…

Mutant p53 in cancer: from molecular mechanism to therapeutic modulation

TP53, a crucial tumor suppressor gene, is the most commonly mutated gene in human cancers. Aside from losing its tumor suppressor function, mutant p53 (mutp53) often acquires inherent, novel oncogenic functions, which is termed “gain-of-function”. Emerging evidence suggests that mutp53 is highly ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiaohua, Zhang, Taotao, Su, Wei, Dou, Zhihui, Zhao, Dapeng, Jin, Xiaodong, Lei, Huiwen, Wang, Jing, Xie, Xiaodong, Cheng, Bo, Li, Qiang, Zhang, Hong, Di, Cuixia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674619/ https://www.ncbi.nlm.nih.gov/pubmed/36400749 http://dx.doi.org/10.1038/s41419-022-05408-1

Ejemplares similares

Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation
por: Dou, Zhihui, et al.
Publicado: (2021)

Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation
por: Wang, Jing, et al.
Publicado: (2023)

RNA-binding protein 39: a promising therapeutic target for cancer
por: Xu, Caipeng, et al.
Publicado: (2021)

Influence of cyclin D1 splicing variants expression on breast cancer chemoresistance via CDK4/CyclinD1‐pRB‐E2F1 pathway
por: Wang, Jing, et al.
Publicado: (2023)

Therapeutic potential of ReACp53 targeting mutant p53 protein in CRPC
por: Zhang, Yaqun, et al.
Publicado: (2019)

Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation
por: Na, Bing, et al.
Publicado: (2019)

New therapeutic strategies to treat human cancers expressing mutant p53 proteins
por: Blandino, Giovanni, et al.
Publicado: (2018)

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
por: Muller, Patricia A.J., et al.
Publicado: (2014)

GOF Mutant p53 in Cancers: A Therapeutic Challenge
por: Dolma, Lobsang, et al.
Publicado: (2022)

Metabolism‐Based Molecular Subtyping Endows Effective Ketogenic Therapy in p53‐Mutant Colon Cancer
por: Tang, Meng, et al.
Publicado: (2022)

Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
por: Zhang, Shengliang, et al.
Publicado: (2022)

Identification of Small Molecules that Modulate Mutant p53 Condensation
por: Lemos, Clara, et al.
Publicado: (2020)

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
por: Schulz-Heddergott, Ramona, et al.
Publicado: (2018)

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
por: Demir, Salih, et al.
Publicado: (2020)

Editorial: Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments
por: Timofeev, Oleg
Publicado: (2021)

Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
por: Chen, Sisi, et al.
Publicado: (2019)

Bifunctional ligand design for modulating mutant p53 aggregation in cancer
por: Miller, Jessica J., et al.
Publicado: (2019)

Ubiquitin ligase TRIM71 suppresses ovarian tumorigenesis by degrading mutant p53
por: Chen, Yajie, et al.
Publicado: (2019)

Cancer therapeutic targeting using mutant–p53-specific siRNAs
por: Ubby, Ifeoma, et al.
Publicado: (2019)

Gain of Function (GOF) Mutant p53 in Cancer—Current Therapeutic Approaches
por: Roszkowska, Katarzyna A., et al.
Publicado: (2022)

A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis
por: Yue, Xuetian, et al.
Publicado: (2016)

Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism
por: Zhou, Ge, et al.
Publicado: (2014)

Modulation of cyclins and p53 in mesangial cell proliferation and apoptosis during Habu nephritis
por: Lu, Yang, et al.
Publicado: (2015)

Updates on p53: modulation of p53 degradation as a therapeutic approach
por: Dey, A, et al.
Publicado: (2008)

Insights into Allosteric Mechanisms of the Lung-Enriched p53 Mutants V157F and R158L
por: Lei, Jiangtao, et al.
Publicado: (2022)

Targeting mutant p53 stabilization for cancer therapy
por: Wang, Jiajian, et al.
Publicado: (2023)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

Author Correction: Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
por: Chen, Sisi, et al.
Publicado: (2020)

Mutant p53 targeting by the low molecular weight compound STIMA‐1
por: Zache, Nicole, et al.
Publicado: (2017)

Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells
por: Cordani, Marco, et al.
Publicado: (2020)

Molecular profiling identifies distinct subtypes across TP53 mutant tumors
por: Chen, Xin, et al.
Publicado: (2022)

Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics
por: Kogan, Samuel, et al.
Publicado: (2018)

Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
por: Alvarado-Ortiz, Eduardo, et al.
Publicado: (2021)

Biomedical Photoacoustic Imaging for Molecular Detection and Disease Diagnosis: “Always‐On” and “Turn‐On” Probes
por: Zeng, Yun, et al.
Publicado: (2022)

Targeting mutant p53 in cancer: the latest insights
por: Di Agostino, Silvia, et al.
Publicado: (2019)

p53’s Extended Reach: The Mutant p53 Secretome
por: Pavlakis, Evangelos, et al.
Publicado: (2020)

Mutant p53 in Cancer Progression and Targeted Therapies
por: Zhu, Gaoyang, et al.
Publicado: (2020)

The Impact of Mutant p53 in the Non-Coding RNA World
por: Di Agostino, Silvia
Publicado: (2020)

A SNP involved in alternative splicing of ABCB1 is associated with clopidogrel resistance in coronary heart disease in Chinese population
por: Zhang, Shasha, et al.
Publicado: (2020)

Precise pancreatic cancer therapy through targeted degradation of mutant p53 protein by cerium oxide nanoparticles
por: Zhang, Hao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b3bkdlkp35dui5u6vrp60rr462